BrainStorm signs LOI with Minaris to manufacture NurOwn

BrainStorm Cell Therapeutics (BCLI) announced that it has signed a Letter of Intent, or LOI, with Minaris Advanced Therapies, a global contract development and manufacturing organization, or CDMO, specializing in cell and gene therapies, to manufacture NurOwn for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn in preparation for clinical trial manufacturing at Minaris’ state-of-the-art facility in Allendale, New Jersey. This partnership supports BrainStorm’s readiness for its planned Phase 3b clinical trial. This partnership enhances BrainStorm’s U.S. based manufacturing capabilities and supports its multicenter Phase 3b clinical trial in the United States. It complements BrainStorm’s recently announced collaboration with Pluri (PLUR) ( PLUR) in Israel, which will also contribute to the production of clinical trial material. Together, these strategic relationships reinforce BrainStorm’s commitment to building a robust and flexible manufacturing network to advance the clinical development of NurOwn.